Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Xencor

Xencor Sees Relative Strength Rating Climb To 77

A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue?

Investors Business Daily

Stocks Showing Rising Market Leadership: Xencor Earns 81 RS Rating

Stocks Showing Rising Market Leadership: Xencor Earns 81 RS Rating

Xencor shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Critical Insights From Xencor Analyst Ratings: What You Need To Know

Critical Insights From Xencor Analyst Ratings: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Xencor (NASDAQ:XNCR) in the last three months.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stocks Showing Rising Market Leadership: Xencor Earns 83 RS Rating

Xencor sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Xencor Meets 80-Plus Relative Strength Rating Benchmark

A Relative Strength Rating upgrade for Xencor shows improving technical performance.

Investors Business Daily

2 Beaten-Down Growth Stocks With 90% or More Upside Potential in 2024

While these stocks have taken a beating this year, Wall Street believes they have major rebound potential in 2024.

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Xencor's Earnings Outlook

Xencor's Earnings Outlook

Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report an earnings per share (EPS) of $-0.60.

Xencor: Q4 Earnings Insights

Xencor: Q4 Earnings Insights

Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor beat estimated earnings by 1310.0%, reporting an EPS of $1.21 versus an estimate of $-0.1.

Organisations

Berkshire Hathaway

Arista Networks

Western Digital

Micron Technology

SherwinWilliams

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play